CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $52.81M, above the global median of $16.24M
- FinancialsAltman Z-Score 1.53: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.78BCNY857.72M · vs all stocks (USD)
Revenue (TTM)
2.37BCNY352.51M · vs all stocks (USD)
Profit Margin
-11.38%Beta
0.2540xvs all stocks
52-Week Change
-10.76%vs all stocks
Market Capitalization
5.78BCNY857.72M · vs all stocks (USD)
Enterprise Value
6.33BCNY939.48M · vs all stocks (USD)
Price to Sales (TTM)
2.43xPrice to Book (MRQ)
5.24xEnterprise to Revenue
2.67xEnterprise to EBITDA
144.31xGross Margin
61.01%Profit Margin
-11.38%Operating Margin
7.89%Return on Assets (TTM)
-2.49%Return on Equity (TTM)
-19.47%Revenue (TTM)
2.37BCNY352.51M · vs all stocks (USD)
Revenue per Share (TTM)
2.23CNYUpdated Aug 20, 2026Quarterly Revenue Growth
20.70%Gross Profit (TTM)
1.22BCNY181.83M · vs all stocks (USD)
EBITDA (TTM)
23.08MCNY3.43M · vs all stocks (USD)
Net Income (TTM)
-270.08MCNY-40.11M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
327.30%Operating Cash Flow (TTM)
238.20MCNY35.38M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
355.56MCNY52.81M · vs all stocks (USD)
5-Year Average Dividend Yield
0.78%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
71.66MCNYFY2025 · Dec 31, 2025Revenue
2.27BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.14BCNYFY2025 · Dec 31, 2025Gross Profit
1.13BCNYFY2025 · Dec 31, 2025Operating Income
-141.55MCNY-21.02M · vs all stocks (USD)
Pre-tax Income
-290.87MCNYFY2025 · Dec 31, 2025Income Tax Expense
-6.35MCNYFY2025 · Dec 31, 2025Net Income
-284.53MCNYFY2025 · Dec 31, 2025EBIT
-235.28MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
23.08MCNYFY2025 · Dec 31, 2025Research & Development
91.60MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
748.80MCNYFY2025 · Dec 31, 2025Other Operating Expenses
32.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
55.59MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.2718CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.2718CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.06BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.06BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-284.53MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-4.05MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-109.65MCNYFY2025 · Dec 31, 2025Free Cash Flow
-138.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
330.27MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-284.53MCNYFY2025 · Dec 31, 2025Other Non-cash Items
66.30MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
33.48MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
75.10MCNYFY2025 · Dec 31, 2025Capital Expenditures
-28.38MCNYFY2025 · Dec 31, 2025Net Acquisitions
104.17MCNYFY2025 · Dec 31, 2025Purchase of Investments
-12.00MCNYFY2025 · Dec 31, 2025Sale of Investments
13.56MCNYFY2025 · Dec 31, 2025Other Investing Activity
46.71MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
124.06MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
948.49MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.21BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-48.98MCNYFY2025 · Dec 31, 2025Other Financing Charges
-25.39MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-335.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.09BSharesUpdated Aug 20, 2026Float Shares
651.26MSharesUpdated Aug 20, 2026% Held by Insiders
40.41%vs all stocks
% Held by Institutions
10.73%vs all stocks
Total Cash (MRQ)
806.45MCNY119.77M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7420CNYUpdated Aug 20, 2026Total Debt (MRQ)
1.23BCNY182.26M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.04xCurrent Ratio (MRQ)
0.7610xBook Value per Share (MRQ)
1.01CNYUpdated Aug 20, 2026Total Assets
3.73BCNY553.28M · vs all stocks (USD)
Total Current Assets
1.93BCNYFY2025 · Dec 31, 2025Total Liabilities
2.49BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.80BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
191.55MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.30BCNYFY2025 · Dec 31, 2025Cash
330.96MCNYFY2025 · Dec 31, 2025Cash Equivalents
219.15MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
550.11MCNYFY2025 · Dec 31, 2025Other Short-term Investments
4.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
429.32MCNYFY2025 · Dec 31, 2025Inventory
323.62MCNYFY2025 · Dec 31, 2025Accounts Payable
499.42MCNYFY2025 · Dec 31, 2025Short-term Debt
948.60MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.66MCNYFY2025 · Dec 31, 2025Long-term Debt
102.07MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
20.07MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.09BCNYFY2025 · Dec 31, 2025Retained Earnings
-378.86MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.24BCNY183.52M · vs all stocks (USD)
52-Week Low
3.70CNYUpdated Aug 20, 202652-Week High
6.04CNYUpdated Aug 20, 202652-Week Change
-10.76%vs all stocks
Beta
0.2540xvs all stocks
50-Day MA
4.59CNYUpdated Aug 20, 2026200-Day MA
4.89CNYUpdated Aug 20, 2026Avg 10-Day Volume
54.92MSharesUpdated Aug 20, 2026Avg 30-Day Volume
53.75MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.2500CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.61Profit Margin: -0.11
Financial Health
Altman Z-Score 1.53: grey zoneSignificant
Altman Z-Score: 1.53
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $52.81M, above the global median of $16.24MNotable
Levered free cash flow (USD): 52,808,274.98Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow